BAM
CORT icon

Belpointe Asset Management’s Corcept Therapeutics CORT Stock Holding History

Belpointe Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-489
Closed -$10.6K – 1120
2023
Q1 		$10.6K Buy
489
+404
+475% +$8.86K ﹤0.01% 2687
2022
Q4 		$1.73K Buy
+85
New +$2.13K ﹤0.01% 3306

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Belpointe Asset Management's CORT Position: Q2 2023 in Review

Belpointe Asset Management sold out of Corcept Therapeutics (CORT) in Q2 2023, closing a stake of 489 shares — an estimated $10.6K sold.

Belpointe Asset Management first reported a position in CORT in Q4 2022 and held it in 2 quarters. The position peaked at $10.6K in Q1 2023. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2023.

  • Belpointe Asset Management reported no remaining Corcept Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 489 Corcept Therapeutics shares in Q2 2023, an estimated $10.6K.
  • Belpointe Asset Management first reported a position in Corcept Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Corcept Therapeutics position peaked at $10.6K in Q1 2023.
  • 224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.